Jane Wasman

Board Director

Director

Rigel Pharmaceuticals Inc Rigel Pharmaceuticals Inc SELLAS Life Sciences Group, Inc.Athersys, INC / NEW

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€30k

▼ Sales (0 ops.)

—

Latest filing published 09 Jan 2026 for SELLAS Life Sciences Group, Inc.. Read the official filing

Filing timeline

BuySale

Jane Wasman

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Jane Wasman: trading record in brief

Jane Wasman (board member) discloses dealings in 3 companies, chiefly SELLAS Life Sciences Group, Inc., Rigel Pharmaceuticals Inc and Athersys, INC / NEW. We count 13 filings; the first trade dates from 19 May 2021 and the latest from 7 January 2026.

No open-market sale appears; the market trades are 1 purchase worth €30k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 12 share grants.

Most recently, on 9 January 2026, the filings show a share grant in SELLAS Life Sciences Group, Inc. The last purchase on record was published on 2 June 2025, which is 503 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.